<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04429191</url>
  </required_header>
  <id_info>
    <org_study_id>JSP-CP-003</org_study_id>
    <nct_id>NCT04429191</nct_id>
  </id_info>
  <brief_title>JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell Transplantation</brief_title>
  <official_title>A Phase 1a/b Study to Evaluate the Safety &amp; Tolerability of JSP191 in Combination With a Regimen of Low Dose Radiation &amp; Fludarabine in Subjects With MDS or AML Undergoing Hematopoietic Cell Transplantation (HCT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jasper Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jasper Therapeutics, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1a/b study to evaluate the safety and tolerability of an antibody&#xD;
      conditioning regimen known as JSP191, in combination with low dose radiation and fludarabine,&#xD;
      in subjects with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) undergoing&#xD;
      allogenic blood stem cell transplantation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1a/b study to evaluate the safety and tolerability of an antibody&#xD;
      conditioning regimen known as JSP191, in combination with low dose radiation and fludarabine&#xD;
      in subjects with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) undergoing&#xD;
      allogenic blood stem cell transplantation.&#xD;
&#xD;
      Blood Stem Cell transplantation offers the only potentially curative therapy for many forms&#xD;
      of Acute Myeloid Leukemia (AML) and for Myelodysplastic Syndrome (MDS). While standard of&#xD;
      care conditioning regimens given prior to blood Stem Cell transplantation, such as standard&#xD;
      TBI/Flu conditioning are well tolerated, they are associated with increased rates of relapse&#xD;
      due to persistence of disease causing Hematopoietic Stem Cells and insufficient graft versus&#xD;
      leukemia effect.&#xD;
&#xD;
      The biological conditioning regimen JSP191 is an antibody that binds to CD117. CD117 is the&#xD;
      receptor for Stem Cell Factor on blood forming cells. CD117 binding to Stem Cell Factor is&#xD;
      critical for survival and maintenance of blood forming stem cells.&#xD;
&#xD;
      The binding of JSP191 to CD117 blocks CD117 from binding to Stem Cell Factor on blood forming&#xD;
      stem cells. In the absence of CD117/Stem Cell Factor binding, hematopoietic stem cells that&#xD;
      are currently occupying the bone marrow niches in MDS/AML patients are depleted.&#xD;
&#xD;
      This study will investigate the safety and tolerability of adding JSP191 (an anti-CD117&#xD;
      monoclonal antibody therapy) to standard TBI/Flu conditioning regimen in adults with AML and&#xD;
      MDS undergoing hematopoietic stem cell transplant.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 8, 2020</start_date>
  <completion_date type="Anticipated">December 8, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 15, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of subjects experiencing adverse events and serious adverse events will be assessed.</measure>
    <time_frame>Up to 1 year post Donor Cell Transplant (28 days dose limiting toxicity period)</time_frame>
    <description>The number of subjects experiencing adverse events and serious adverse events will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The number of dose limiting toxicities will be assessed.</measure>
    <time_frame>Up to 1 year post Donor Cell Transplant (28 days dose limiting toxicity period)</time_frame>
    <description>The number of dose limiting toxicities will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The type of dose limiting toxicities will be assessed.</measure>
    <time_frame>Up to 1 year post Donor Cell Transplant (28 days dose limiting toxicity period)</time_frame>
    <description>The type of dose limiting toxicities will be assessed.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>MYELODYSPLASTIC SYNDROME; MDS</condition>
  <condition>ACUTE MYELOID LEUKEMIA; AML</condition>
  <arm_group>
    <arm_group_label>Blood Stem Cell Transplant w/ anti-CD117 conditioning</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The phase 1a portion of the study plans to assess approximately 3 planned dose cohorts of JSP191: 0.3 mg/kg, 0.6 mg/kg, and 1.0 mg/kg to determine the maximum tolerated dose for expansion. Subjects will receive a single dose of intravenous JSP191 antibody followed by monitoring for antibody clearance. Once the antibody has cleared below a certain level, patients will receive stem cell transplant and be monitored for hematopoietic recovery.&#xD;
The phase 1b portion of the study will enroll additional subjects at the expansion dose in order to further explore the safety, feasibility, and PK of that dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Humanized anti-CD117 Monoclonal Antibody (JSP191)</intervention_name>
    <description>Procedure: single intravenous infusion of JSP191 antibody</description>
    <arm_group_label>Blood Stem Cell Transplant w/ anti-CD117 conditioning</arm_group_label>
    <other_name>JSP191</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  AML/MDS as defined by specific criteria, including but not limited to the following&#xD;
             subtypes:&#xD;
&#xD;
               1. AML in CR&#xD;
&#xD;
               2. MDS &lt; 5% BM blasts&#xD;
&#xD;
               3. MDS 5 - 10% BM blasts&#xD;
&#xD;
               4. AML not in CR or MDS &gt; 10% BM blasts&#xD;
&#xD;
          -  Patients with human leukocyte antigen (HLA) matched related or unrelated donors&#xD;
&#xD;
          -  Adequate end organ function as defined in study protocol&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Patients with any acute or uncontrolled infections&#xD;
&#xD;
          -  Patients receiving any other investigational agents&#xD;
&#xD;
          -  Patients with active non-hematologic malignancy&#xD;
&#xD;
          -  Prior allogeneic hematologic cell transplantation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lori Muffly, MD,MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrew Artz, MD,MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>City of Hope Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bart Scott, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Catherine Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Huntsman Cancer Institute/ University of Utah</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arpita Gandhi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ankur Varma, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rush University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials, Jasper Therapeutics, Inc.</last_name>
    <phone>650-549-1417</phone>
    <email>ClinicalTrials@JasperTherapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Lim, MD, MS</last_name>
      <email>nlim@coh.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lori Muffly, MD,MS</last_name>
      <email>lmuffly@stanford.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ankur Varma, MD, MPH</last_name>
      <email>ankur_varma@rush.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Information Line</last_name>
      <phone>503-494-1080</phone>
      <email>trials@ohsu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute - University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Lee, MD</last_name>
      <email>cancerinfo@hci.utah.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bart Scott, MD</last_name>
      <email>bscott@fredhutch.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 10, 2020</study_first_submitted>
  <study_first_submitted_qc>June 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2020</study_first_posted>
  <last_update_submitted>June 8, 2021</last_update_submitted>
  <last_update_submitted_qc>June 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ACUTE MYELOID LEUKEMIA</keyword>
  <keyword>AML</keyword>
  <keyword>MDS</keyword>
  <keyword>MYELODYSPLASTIC SYNDROME</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

